Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
FibroGen (FGEN)
NASDAQ:FGEN
Holding FGEN?
Track your performance easily
FGEN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.33 - $2.93
Previous Close$0.42
Volume505.08K
Average Volume (3M)2.24M
Market Cap
$41.16M
Enterprise Value$89.81M
Total Cash (Recent Filing)$140.71M
Total Debt (Recent Filing)$146.38M
Price to Earnings (P/E)―
Beta1.90
Next Earnings
Nov 04, 2024EPS Estimate
-$0.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.71
Shares Outstanding100,400,786
10 Day Avg. Volume924,967
30 Day Avg. Volume2,238,101
Standard Deviation0.29
R-Squared0.02
Alpha-0.04
Financial Highlights & Ratios
Price to Book (P/B)-0.18
Price to Sales (P/S)0.26
Price to Cash Flow (P/CF)-0.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.52
Enterprise Value/Gross Profit0.70
Enterprise Value/Ebitda-0.62
Forecast
1Y Price Target
$0.60Price Target Upside46.34% Upside
Rating ConsensusModerate Sell
Number of Analyst Covering1
FibroGen News
PremiumCompany Announcements
FibroGen Announces Board Member Resignations and Committee Appointments
PremiumCompany Announcements
FibroGen Executives Depart Amid U.S. Operations Overhaul
Bulls Say, Bears Say
Bulls Say
Clinical TrialsUpcoming readouts from the LAPIS and PanCAN Precision Promise studies of pamrevlumab in pancreatic cancer as the nearest term clinical catalysts for the company.
Regulatory ApprovalPotential approval for use in chemotherapy-induced anemia (CIA) before the year-end.
Revenue GrowthProduct revenue guidance raised amid solid roxadustat growth in China.
Bears Say
Biomarker StrategyHighlight the yet-to-be validated biomarker strategy and mixed data to-date from both the monotherapy and combination studies of FG-3246 as factors hindering the ability to gain more conviction on the asset.
Development PathClarity on the development path of FG-3246 remains limited as details such as dose and patient selection are yet to be finalized.
Oncology PipelineFurther clarity on the oncology pipeline as a whole is awaited.
---
Ownership Overview
7.10% Insiders
28.98% Mutual Funds
35.17% Other Institutional Investors
28.74% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
FGEN FAQ
What was FibroGen’s price range in the past 12 months?
FibroGen lowest stock price was $0.33 and its highest was $2.93 in the past 12 months.
What is FibroGen’s market cap?
Currently, no data Available
When is FibroGen’s upcoming earnings report date?
FibroGen’s upcoming earnings report date is Nov 04, 2024 which is in 45 days.
How were FibroGen’s earnings last quarter?
FibroGen released its earnings results on Aug 06, 2024. The company reported -$0.16 earnings per share for the quarter, beating the consensus estimate of -$0.32 by $0.16.
Is FibroGen overvalued?
According to Wall Street analysts FibroGen’s price is currently Undervalued.
Does FibroGen pay dividends?
FibroGen does not currently pay dividends.
What is FibroGen’s EPS estimate?
FibroGen’s EPS estimate is -$0.31.
How many shares outstanding does FibroGen have?
FibroGen has 100,400,790 shares outstanding.
What happened to FibroGen’s price movement after its last earnings report?
FibroGen reported an EPS of -$0.16 in its last earnings report, beating expectations of -$0.32. Following the earnings report the stock price went up 4.545%.
Which hedge fund is a major shareholder of FibroGen?
Among the largest hedge funds holding FibroGen’s share is PRIMECAP Management Co. It holds FibroGen’s shares valued at 12M.
---
FibroGen Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Sell
Average Price Target:
$0.60 (46.34% Upside)
$0.60 (46.34% Upside)
Blogger Sentiment
Bearish
FGEN Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 675.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.4%
Last 30 Days ▼ 6.5%
Last 30 Days ▼ 6.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-46.83%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-43.08%
Trailing 12-Months
Company Description
FibroGen
FibroGen, Inc. engages in the discovery, development, and commercialization of therapeutics. It focuses on hypoxia-inducible factor and connective tissue growth factor biology to develop innovative medicines for the treatment of anemia, fibrotic disease, and cancer. The company was founded by Thomas B. Neff on September 29, 1993 and is headquartered in San Francisco, CA.
---
FGEN Company Deck
---
FGEN Earnings Call
Q2 2024
0:00 / 0:00
---
FGEN Stock 12 Month Forecast
Average Price Target
$0.60
▲(46.34% Upside)
Technical Analysis
Adaptimmune Therapeutics
―
Atara Biotherapeutics
―
Akebia Therapeutics
―
Arrowhead Pharmaceuticals
―
Best Analysts Covering FGEN
1 Year
1 Year Success Rate
11/14 ratings generated profit
1 Year Average Return
+38.16%
reiterated a sell rating last month
Copying Paul Choi's trades and holding each position for 1 Year would result in 78.57% of your transactions generating a profit, with an average return of +38.16% per trade.
---